Parkinson’s disease - search results

Herantis Pharma is an innovative biotech company developing disease-modifying therapies for Parkinson’s disease.

COVID-19 activates the same inflammatory response in the brain as Parkinson’s disease – increasing the risk of future potential neurodegenerative conditions.

Dr Rutger Zietsma – CEO at Manus Neurodynamica Ltd – and PD Dr Angela Deutschländer share their vision on earlier diagnosis and objective symptom tracking with the NeuroMotor PenTM.

Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.

A new study published in the Movement Disorders journal, has paved the way for more research into identifying markers of progression for patients in the early stages of Parkinson’s disease

Ramón Cacabelos, President of EuroEspes Biomedical Research Centre looks at conventional pharmacological treatments for Parkinson’s disease

The European Parkinson’s Disease Association (EPDA) sheds light on the challenges of the disease and the My PD Journey project which focuses on ways to improve accessibility and treatment… Parkinson’s disease is a progressive, chronic and complex neurodegenerative disease (NDD) that affects all aspects of daily living; it is the...

Ramón Cacabelos, President, EuroEspes Biomedical Research Center says it is time to rethink the causes and treatments for Parkinson's disease... It is highly unlikely that James Parkinson (1755-1824), who first described the “paralysis agitans” in his ‘An Essay on the Shaking Palsy’ in 1817 (years later rebadged by Jean-Martin Charcot as Parkinson’s...

National Institutes of Health scientists develop new brain disease test for the early diagnosis of Parkinson’s disease and dementia with Lewy bodies The group, led by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson’s disease, 17 from...

We spoke with Parkinson’s UK, an organisation dedicated to funding important research and supporting those affected by Parkinson’s, about the prevalence, impact, and management of the condition.

Richard J. Miller, PhD, Professor Emeritus of Pharmacology at Northwestern University Feinberg School of Medicine, says that the belief monkeys and other animals are essential for performing translationally useful research for human neurological disease is outdated and incompatible with 21st-century science.

Parkinson’s disease, a progressive neurodegenerative disorder, poses significant challenges for both patients and researchers. In a recent interview with Henri Huttunen from Herantis Pharma Plc, we delved into the intricacies of their potential novel disease-modifying therapy, HER-096.

Markus Mandler, Founder and CEO of Tridem Bioscience, explains how the company’s cutting-edge vaccine platform is revolutionising treatment approaches and vaccines for non-communicable diseases (NCDs).

In 1980, hundreds of individuals reported to emergency clinics in Northern California complaining of tremors, motility problems, and mild cognitive deficits - all classic signs of Parkinson’s disease (PD)

Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc, charts progress in the development of disease-modifying treatments for Parkinson’s disease.

Bradlee Heckmann, PhD, from USF Health Neuroscience Institute, Byrd Alzheimer’s Center & Asha Therapeutics, in this discussion goes beyond amyloid, asking what’s next for Alzheimer’s Disease therapeutics.

Efforts to prevent or treat Alzheimer’s Disease (AD) by targeting Amyloid beta (Aβ) assemblies should be continued, but the strategies should be altered dramatically.

Parkinson’s Disease affects all activities of patient daily living but PKG can help.

The annual worldwide cost of treating amyloid-associated diseases is about a trillion dollars and increasing steadily. But the human toll is worse Amyloids are killing us, both literally and financially. Consider just these three: Amyloid β (Aβ) in Alzheimer’s Disease, α-Synuclein (α-Syn) in Parkinson’s Disease, and Amylin (aka IAPP) in...

Dr Deborah Lee from Dr Fox Online Pharmacy, considers the role of physical activity to prevent chronic diseases